Development of Prototype Filovirus Recombinant Antigen Immunoassays.

ABSTRACT:

Background

Throughout the 2014-2015 Ebola outbreak in West Africa, major gaps were exposed in the availability of validated rapid diagnostic platforms, protective vaccines, and effective therapeutic agents. These gaps potentiated the development of prototype rapid lateral flow immunodiagnostic (LFI) assays that are true point-of-contact platforms, for the detection of active Ebola infections in small blood samples.

Methods

Recombinant Ebola and Marburg virus matrix VP40 and glycoprotein (GP) antigens were used to derive a panel of monoclonal and polyclonal antibodies. Antibodies were tested using a multivariate approach to identify antibody-antigen combinations suitable for enzyme-linked immunosorbent assay (ELISA) and LFI assay development.

Results

Polyclonal antibod

SUBMITTER: Boisen ML 

PROVIDER: S-EPMC4564556 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature